See discussions, stats, and author profiles for this publication at: https://www.researchgate.

net/publication/275272889

Serum procalcitonin as a tumoral marker in small cell lung cancer.

Conference Paper · June 2011

CITATIONS READS

0 157

6 authors, including:

Maxime Patout Valéry Brunel

Centre Hospitalier Universitaire Rouen Centre Hospitalier Universitaire Rouen
155 PUBLICATIONS   662 CITATIONS    75 PUBLICATIONS   190 CITATIONS   

SEE PROFILE SEE PROFILE

Suzanna Bota
Centre Hospitalier Universitaire Rouen
70 PUBLICATIONS   1,041 CITATIONS   

SEE PROFILE

Some of the authors of this publication are also working on these related projects:

Laboratory Medicine and General Biochemistry at CHU ROUEN View project

Esogia View project

All content following this page was uploaded by Valéry Brunel on 18 July 2015.

The user has requested enhancement of the downloaded file.

84113-102 http://meetinglibrary.asco.org/print/572934

Published on Meeting Library (http://meetinglibrary.asco.org)

Home > 84113-102

Serum procalcitonin as a tumoral marker in small cell lung cancer.

Meeting:
2011 ASCO Annual Meeting

Category:
Lung Cancer - Local-Regional and Adjuvant Therapy/Small Cell

Subcategory:
Adjuvant Therapy

Session Type and Session Title:

This abstract will not be presented at the 2011 ASCO Annual Meeting but has been published in
conjunction with the meeting.

Abstract Number:
e17525

Citation:
J Clin Oncol 29: 2011 (suppl; abstr e17525)

Author(s):
M. Patout, V. Brunel, M. Salaun, S. Bota, B. Cauliez, L. Thiberville; Rouen University Hospital, Rouen,
France; CHU de Rouen, Hôpital Charles Nicolle, Rouen, France; CHU Pneumologie, Rouen, France

Background: Procalcitonin (PCT) is indicated for the early diagnosis of bacterial infections. Procalcitonin
is also considered as a marker for the follow-up of thyroid carcinoma and has been found increased in
patients with liver metastases. No previous study has assessed PCT in lung cancer. The aim of this study
was to evaluate serum PCT as a tumoral marker for small cell lung cancer, and as a marker of liver
metastasis. Methods: Sera from the Rouen University Hospital Biological Bank taken from patients that
were also sampled for neurone specific enolase (NSE) were retrieved. Samples from patients with
histologically proven lung cancer, taken before any treatment between December 2008 and November
2010 were selected for the study Results: From the 147 blood samples selected, 66 came from
adenocarcinoma patients, 58 from neuroendocrine lung cancers (NELC) including 51 small cell lung
cancers, 6 large cell lung cancers and one atypical carcinoid, 21 from squamous cell carcinomas and 2
sarcomas. Mean and median serum PCT were higher in NELC (39 ± 186 ng/ml, and 0.35 ng/ml
(0.11-1.23), respectively) as compared to adecarcinoma (1.01 ± 5 and 0.08 [0.05-0.14]), or squamous cell
carcinoma (0.39 ± 1.08 ng/ml and 0.1 [0.06-0.19]). From this lung cancer series, a level of 5 ng/ml PCT
had a sensitivity of 18 %, and a specificity of 98 % for NELC histology. ROC under curve area for NELC
was 0.764 (p < 0.001). ROC under curve area of NSE for NELC was 0.939. In lung cancer from any
histology with liver metastasis, a level of 0.153 ng/ml PCT had a sensitivity of 70.4%, a specificity of
70.2% (p < 0.001), a positive and negative predictive value of 53 and 67.7%, a positive and negative
likehood ratio of 2.32 and -0.002. ROC under curve area was 0.749 (p < 0.001). ROC under curve area of
NSE for liver metastasis was 0.759. Conclusions: PCT as lower sensitivity and specificity than NSE for
the diagnosis of NELC, and a similar increase than NSE in liver metastases. Serum PCT should not be used
for the early diagnosis of bacterial infection in patients with a NELC and/or with liver metastasis.

Source URL: http://meetinglibrary.asco.org/content/84113-102

1 sur 1 View publication stats

18/07/2015 12:40